Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "Ibrutinib"

AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients
Nasdaq

Transplant Patients Show Improvement With Imbruvica

- By Alberto Abaterusso AbbVie Inc. (ABBV) announced Tuesday through PR Newswire the results indicate ibrutinib (trade name Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from "chronic graft-versus-host disease ... Yahoo! Finance, 4 hours ago
[x]  

29 images for Ibrutinib

Med India, 1 day ago
Cancer Therapy Advisor, 5 days ago
Cancer Therapy Advisor, 5 days ago
Targeted Oncology, 20 hours ago
Nasdaq, 1 day ago
LLS Community, 4 days ago
Targeted Oncology, 5 days ago
Ariva.de, 6 days ago
European Pharmaceutical Review, 1 week ago
OnMedicanet, 2 weeks ago
Targeted Oncology

TGR-1202 Combined With Ibrutinib Demonstrates High Response Rate in CLL/MCL

Matthew S. Davids, MD Combining the PI3 kinase inhibitor TGR-1202 and ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) demonstrated a high response rate without ...
 Targeted Oncology20 hours ago BRIEF-TG Therapeutics presents phase 1b data for TGR-1202 in combination with ibrutinib  Reuters UK4 days ago TG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting  Nasdaq4 days ago Juno Shows Off Positive Early Data in Leukemia Patients  BioSpace4 days ago
[x]  
MedIndia

Blood Cancer Drug 'Ibrutinib' Shows Promise For Treating Graft Versus Host Disease

Highlights Graft Versus Host Disease(GVHD) usually occurs after Stem Cell Transplantation. Researchers find blood cancer drug 'ibrutinib' to have promising potential in treating graft versus host disease after stem cell transplantation. Around ...
 MedIndia1 day ago

BRIEF-AbbVie reports positive Phase 2 data for ibrutinib in cGVHD patients

n"Dec 6 Abbvie Inc : * Late-Breaking ibrutinib (imbruvica) data show complete or partial response in two-thirds of patients with chronic graft-versus-host-disease, a frequent and potentially life-threatening complication of stem cell transplant * ...
 Reuters UK3 days ago BRIEF-AbbVie repоrts pоsitive Phase 2 data fоr ibrutinib in cGVHD patients  NewspaperPost3 days ago

Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

89% of study patients, including those with high-risk CLL/SLL, responded to therapy Durable and improving responses also seen in longer follow-up from Phase 3 RESONATE-2 trial This release corresponds to abstracts #233, #234, #2042, #4383 PR ...
 BioSpace4 days ago Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)  Yahoo! Finance5 days ago
[x]  
European Pharmaceutical Review

Price drop means leukaemia CDF drug will be routinely available

The has said that ibrutinib (Imbruvica, Janssen) should be routinely available to some people with chronic lymphocytic leukaemia (CLL). Ibrutinib had only previously been available through the Cancer Drugs Fund (CDF). Following a reduction in its ...
 European Pharmaceutical Review1 week ago Green light for leukaemia drug after price cut  BootsWebMD2 weeks ago NICE Rejects Ibrutinib for Waldenström Macroglobulinemia  ASH Clinical News1 month ago
Freshnews.com

ASH 2016: Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions

RARITAN, N.J., Nov. 3, 2016 /PRNewswire/ -- New data for the first-in-class BTK inhibitor ibrutinib and immunotherapy daratumumab are among the 13 oral presentations from Janssen Research & Development, LLC to be featured at the 58 th American ...
 Yahoo! Singapore1 month ago ASH 2016 : Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions  4 Traders1 month ago
[x]  
Targeted Oncology

52 Month Median PFS with Ibrutinib in Patients with Relapsed/ Refractory in CLL

ASHReport has 68 videos Subscribe Here Loading........ Video URL : Embed : Description: Susan M. O'Brien, MD of University of California Irvine, gives an overview of Abstract 233: Five-Year Experience with Single-Agent Ibrutinib in Patients ...
 Oncology Tube22 hours ago Five-Year Experience with Single-Agent Ibrutinib  Oncology Tube22 hours ago An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation  Targeted Oncology3 days ago Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation  Targeted Oncology5 days ago

Responses Are High/Durable for Ibrutinib in Chronic Graft Versus Host Disease: Presented at ASH

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 23 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma23 hours ago ASH 2016: Ibrutinib helpful in treating graft versus host disease after stem cell transplant  Ecancer Medicalscience3 days ago Cancer drug ibrutinib found helpful in treating graft versus host disease after transplant  EurekAlert!3 days ago Highly Anticipated Late-Breaking Abstracts Session to Feature Groundbreaking Scientific Data During 58th ASH Annual Meeting  TickerTech.com3 days ago
[x]  
Ecancer Medicalscience

CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity. Published Online : December 06, 2016 Surabhi ...
 American Journal of Managed Care3 days ago The Latest on Chimeric Antigen Receptor Therapy for Leukemia  Longevity Meme3 days ago CAR T-Cell Immunotherapy Proves a Plus in Treatment-Resistant Chronic Lymphocytic Leukemia  Genetic Engineering News4 days ago Novel Therapy Yields High Responses in Treatment-Resistant Chronic Lymphocytic Leukemia  MedIndia4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less